Airsonett has developed Protexo based on the TLA (Temperature controlled Laminar Airflow) technology, which breaks the body convection and thus creates an allergen free zone, where it is important – in the breathing zone.
Protexo significantly reduces the inhalant allergen level during sleep and gives the hyperactive immune system of a person suffering from asthma long, frequent periods of critical recovery:
Protexo is the first ever evidence-based non-pharmaceutical treatment of atopic asthma. It is non-invasive and has an excellent safety profile.
You can read more about Protexo and the TLA technology on the next section.